BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27318861)

  • 1. The optimal timing of surgical resection in high-risk neuroblastoma.
    Rojas Y; Jaramillo S; Lyons K; Mahmood N; Wu MF; Liu H; Vasudevan SA; Guillerman RP; Louis CU; Russell HV; Nuchtern JG; Kim ES
    J Pediatr Surg; 2016 Oct; 51(10):1665-9. PubMed ID: 27318861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months.
    Fischer J; Pohl A; Volland R; Hero B; Dübbers M; Cernaianu G; Berthold F; von Schweinitz D; Simon T
    BMC Cancer; 2017 Aug; 17(1):520. PubMed ID: 28778185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of surgery in the treatment of patients with high-risk neuroblastoma who have a poor response to induction chemotherapy.
    Du L; Liu L; Zhang C; Cai W; Wu Y; Wang J; Lv F
    J Pediatr Surg; 2014 Apr; 49(4):528-33. PubMed ID: 24726106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study.
    Holmes K; Pötschger U; Pearson ADJ; Sarnacki S; Cecchetto G; Gomez-Chacon J; Squire R; Freud E; Bysiek A; Matthyssens LE; Metzelder M; Monclair T; Stenman J; Rygl M; Rasmussen L; Joseph JM; Irtan S; Avanzini S; Godzinski J; Björnland K; Elliott M; Luksch R; Castel V; Ash S; Balwierz W; Laureys G; Ruud E; Papadakis V; Malis J; Owens C; Schroeder H; Beck-Popovic M; Trahair T; Forjaz de Lacerda A; Ambros PF; Gaze MN; McHugh K; Valteau-Couanet D; Ladenstein RL;
    J Clin Oncol; 2020 Sep; 38(25):2902-2915. PubMed ID: 32639845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Clinical Management and Outcomes of Pelvic Neuroblastic Tumors.
    Zobel M; Zamora A; Sura A; Wang L; Stein J; Marachelian A; Kim ES
    J Surg Res; 2020 May; 249():8-12. PubMed ID: 31918331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study.
    Adkins ES; Sawin R; Gerbing RB; London WB; Matthay KK; Haase GM
    J Pediatr Surg; 2004 Jun; 39(6):931-6. PubMed ID: 15185228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641.
    Strother DR; London WB; Schmidt ML; Brodeur GM; Shimada H; Thorner P; Collins MH; Tagge E; Adkins S; Reynolds CP; Murray K; Lavey RS; Matthay KK; Castleberry R; Maris JM; Cohn SL
    J Clin Oncol; 2012 May; 30(15):1842-8. PubMed ID: 22529259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of surgical resection in children with high-risk neuroblastoma.
    Englum BR; Rialon KL; Speicher PJ; Gulack B; Driscoll TA; Kreissman SG; Rice HE
    Pediatr Blood Cancer; 2015 Sep; 62(9):1529-35. PubMed ID: 25810376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete surgical resection combined with aggressive adjuvant chemotherapy and bone marrow transplantation prolongs survival in children with advanced neuroblastoma.
    Chamberlain RS; Quinones R; Dinndorf P; Movassaghi N; Goodstein M; Newman K
    Ann Surg Oncol; 1995 Mar; 2(2):93-100. PubMed ID: 7728576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes in children with adrenal neuroblastoma undergoing open versus laparoscopic adrenalectomy.
    Kelleher CM; Smithson L; Nguyen LL; Casadiego G; Nasr A; Irwin MS; Gerstle JT
    J Pediatr Surg; 2013 Aug; 48(8):1727-32. PubMed ID: 23932613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).
    Zhou MJ; Doral MY; DuBois SG; Villablanca JG; Yanik GA; Matthay KK
    Eur J Cancer; 2015 Nov; 51(16):2465-72. PubMed ID: 26254811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
    Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
    J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004.
    Schmidt M; Simon T; Hero B; Eschner W; Dietlein M; Sudbrock F; Bongartz R; Berthold F; Schicha H
    Nuklearmedizin; 2006; 45(4):145-51; quiz N39-40. PubMed ID: 16964339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of early resection of primary neuroblastoma on the survival of children older than 1 year of age with stage 4 disease: the St. Jude Children's Research Hospital Experience.
    McGregor LM; Rao BN; Davidoff AM; Billups CA; Hongeng S; Santana VM; Hill DA; Fuller C; Furman WL
    Cancer; 2005 Dec; 104(12):2837-46. PubMed ID: 16288490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of surgery in stage IV neuroblastoma.
    Castel V; Tovar JA; Costa E; Cuadros J; Ruiz A; Rollan V; Ruiz-Jimenez JI; Perez-Hernández R; Cañete A
    J Pediatr Surg; 2002 Nov; 37(11):1574-8. PubMed ID: 12407542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management and outcome of stage 3 neuroblastoma.
    Modak S; Kushner BH; LaQuaglia MP; Kramer K; Cheung NK
    Eur J Cancer; 2009 Jan; 45(1):90-8. PubMed ID: 18996003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single center clinical analysis of children with high-risk neuroblastoma.
    Tian X; Cao Y; Wang J; Yan J; Tian Y; Li Z; Wang H; Duan X; Jin Y; Zhao Q
    Oncotarget; 2017 May; 8(18):30357-30368. PubMed ID: 28423674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.
    Oesterheld J; Ferguson W; Kraveka JM; Bergendahl G; Clinch T; Lorenzi E; Berry D; Wada RK; Isakoff MS; Eslin DE; Brown VI; Roberts W; Zage P; Harrod VL; Mitchell DS; Hanson D; Saulnier Sholler GL
    J Clin Oncol; 2024 Jan; 42(1):90-102. PubMed ID: 37883734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multivariate analysis of risk factors for patients with stage 4 neuroblastoma who were older than 18 months at diagnosis: a report from a single institute in Shanghai, China.
    Cai J; Pan C; Tang Y; Chen J; Zhou M; Li B; Xue H; Shen S; Gao Y; Zhang A; Tang J
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1327-1335. PubMed ID: 28283783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group.
    Naranjo A; Parisi MT; Shulkin BL; London WB; Matthay KK; Kreissman SG; Yanik GA
    Pediatr Blood Cancer; 2011 Jul; 56(7):1041-5. PubMed ID: 21328522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.